At a meeting in Houston, the AMA's House of Delegates adopted a new policy that calls for "marijuana's status as a federal Schedule I controlled substance be reviewed with the goal of facilitating the conduct of clinical research and development of cannabinoid-based medicines, and alternate delivery methods."
That does not mean the AMA supports the legalization or decriminalization of marijuana.
Schedule I drugs are those considered to have no medical benefit and to be harmful when used under any circumstances. As such, marijuana is currently grouped by the federal government with drugs like heroin and LSD. By comparison, cocaine and methamphetamines are classified as Schedule II drugs, which may have some clinical benefits when used in the proper circumstances. The AMA's stance could simply result in the rescheduling of marijuana as a controlled substance that has some medical benefit.
However, Aaron Houston, director of government relations for the Marijuana Policy Project, calls the move "historic" all the same, noting that it comes from "what has historically been America's most cautious and conservative major medical organization."